ArticlePsychiatric services (Washington, D.C.)2025
Differential Changes in Use of Medications for Opioid Use Disorder by Race-Ethnicity: Effects of a Hub-and-Spoke Model.
Article in Psychiatric services (Washington, D.C.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveThe authors examined, separately for different racial-ethnic groups, whether use of medications for opioid use disorder (MOUD) increased more among people treated in a hub-and-spoke care model than among people treated in a non-hub-and-spoke model.
methodsComparative time-series analyses were performed with Washington State Medicaid claims (2017-2019) data for 115,911 enrollees to investigate MOUD use, stratified by care model and enrollee race-ethnicity.
resultsFollowing implementation of the hub-and-spoke model, the proportions of enrollees with opioid use disorder receiving MOUD increased in all racial-ethnic groups. Buprenorphine use increased more among Black, Hispanic, and White enrollees treated in the hub-and-spoke model than among people of the same race-ethnicities treated in a non-hub-and-spoke model (beta range 0.56-0.93, p<0.05). However, within the hub-and-spoke model, rates of buprenorphine use increased more among White enrollees than among American Indian or Alaska Native (AI/AN) enrollees (β=0.84, p<0.001). Methadone use increased more among AI/AN enrollees treated in the hub-and-spoke model compared with AI/AN enrollees treated in a non-hub-and-spoke model (β=0.39, p<0.001).
conclusionsFollowing implementation of the hub-and-spoke model, MOUD use increased for Medicaid enrollees of all race-ethnicities. The increase in MOUD use for Black, Hispanic, and White enrollees who received treatment in the hub-and-spoke model was greater than that for people of the same race-ethnicities treated in a non-hub-and-spoke model. Thus, the hub-and-spoke model may be a useful strategy to increase use of MOUD treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.